bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath Lung Cancer Diagnostic Study to evaluate clinical performance of CyPath Lung for the early detection of

bioAffinity Technologies Announces Initiation

of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath Lung Cancer Diagnostic

Study to evaluate clinical performance of

CyPath Lung for the early detection of lung cancer in high-risk patients

Murtha Cancer Center Research Program at

Uniformed Services University of the Health Sciences provides support for longitudinal study

ANTONIO, TX - March 10, 2026 - bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused

on non-invasive diagnostics and early cancer detection, today announced initiation of the Company's planned large-scale, longitudinal

clinical study for CyPath Lung, its noninvasive diagnostic test for the detection of early-stage lung cancer.

The 2,000-patient longitudinal study is designed

to evaluate the clinical performance of the CyPath Lung flow cytometry test as a noninvasive diagnostic that uses sputum samples

to detect the presence of lung cancer in high-risk individuals with existing lung nodules six millimeters (mm) to less than 30 mm in

diameter identified by lung cancer screening. In an earlier clinical trial, CyPath Lung showed 92% sensitivity, 87% specificity

and 88% accuracy in detecting lung cancer in patients with small pulmonary nodules less than 20mm. Several recent patient case studies

demonstrate the test's ability to detect lung cancer at its curative Stage 1A.

bioAffinity Technologies expects up to 20 clinical study sites, including

a dozen Department of Veterans Affairs (VA) medical centers and two of the nation's largest military hospitals, will participate

in the study. Michael J. Morris, MD, pulmonology and critical care physician at Brooke Army Medical Center, is the national Principal

Investigator for the study (NCT07168993). The John P. Murtha Cancer Center Research Program (MCCRP),

a research program within the Department of Surgery at the Uniformed Services University of the Health Sciences in Bethesda, Maryland,

is providing support and funding associated with the trial at several federal facilities.

Physicians currently order CyPath Lung, a laboratory developed

test (LDT) offered by bioAffinity Technologies' subsidiary Precision Pathology Laboratory Services, for their patients with indeterminate

lung nodules to determine next steps in patient care.

The longitudinal clinical trial announced today will evaluate FlowPath

Lung, a research-use test that uses the same technology and follows the same procedures as CyPath Lung. The different name is simply

used to distinguish the investigational assay from the commercially available test.

"As more indeterminate pulmonary nodules are found either incidentally

or by routine lung cancer screening, CyPath Lung can fill the diagnostic gap between watchful waiting' and invasive

procedures that carry risk," said Gordon Downie, MD, PhD, Chief Medical Officer of bioAffinity Technologies. "As a result,

we see growing adoption and use of CyPath Lung by physicians and expect this longitudinal trial to provide additional evidence to

support inclusion of our noninvasive test as part of the standard of care for lung cancer screening and diagnosis."

"Initiating this study represents an important milestone for

CyPath Lung," said Maria Zannes, President and CEO of bioAffinity Technologies. "By following patients longitudinally

across multiple sites, we expect to acquire robust, real-world data that reflects how CyPath Lung may be used to support risk assessment

and clinical decision-making aligned with our objective to establish CyPath Lung as a standard of care for evaluating patients at

high-risk for early-stage lung cancer."

The study includes participation from several federal facilities to

examine the test's performance in diverse patient populations, including military service members and veterans. Patient enrollment is

expected to take up to 18 months with patients followed for up to 24 months or until a definitive diagnosis of cancer or no cancer is

CyPath Lung is a non-invasive

test designed to improve the early detection of lung cancer in patients at high risk for the disease. CyPath Lung uses

advanced flow cytometry and proprietary artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy.

CyPath Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells.

Clinical study results demonstrated 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at

high risk for the disease who had small indeterminate lung nodules less than 20 millimeters.

About bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. addresses the

need for non-invasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's

first product, CyPath Lung, is a non-invasive test that has shown high sensitivity, specificity and accuracy for

the detection of early-stage lung cancer. CyPath Lung is marketed as a Laboratory Developed Test (LDT) by Precision

Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking

statements" within the meaning of the federal securities laws. Words such as "may," "might," "will,"

"should," "believe," "expect," "anticipate," "estimate," "continue," "predict,"

"forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent,

belief, or current expectations, are forward-looking statements. These forward-looking statements are subject to various risks and uncertainties,

many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions

from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially

from current expectations include, among others, the ability of CyPath Lung to identify lung cancer in difficult-to-diagnose patients;

the benefits of adding CyPath Lung to the standard of care for evaluating indeterminate lung nodules; CyPath Lung providing

clarity when imaging and risk models are inconclusive; the ability to initiate and conduct the study as planned; challenges in patient

identification, enrollment, retention, and protocol adherence; site performance and operational execution; variability in study data and

outcomes; the possibility that study results do not demonstrate the anticipated performance or clinical utility; changes in standards

of care, competitive developments, or technological advances; delays or difficulties in obtaining, maintaining, or expanding regulatory

approvals or clearances; manufacturing, quality, supply chain, and scaling challenges; reimbursement and coverage uncertainties; the ability

to obtain clinician and patient adoption; and the other factors discussed in the Company's Annual Report on Form 10-K for the year

ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking

statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and

conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not

to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release,

and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press

release, except as may be required by applicable securities laws.

bioAffinity Technologies

Director of Communications